Single-cell immune profiling reveals distinct immune response in asymptomatic COVID-19 patients

Xiang-Na Zhao(Chinese Center For Disease Control and Prevention), Yue You(The University of Melbourne), Xiaoming Cui(Institute of Microbiology), Huixia Gao(Hebei Medical University), Guolin Wang(Institute of Microbiology), Shengbo Zhang(The University of Melbourne), Yao Lin(Institute of Microbiology), Li‐Jun Duan(Institute of Microbiology), Ka-Li Zhu(Institute of Microbiology), Yuling Wang(Hebei Medical University), Li Li(Hebei Medical University), Jianhua Lu(Hebei Medical University), Haibin Wang(Hebei Medical University), Jingfang Fan(Hebei Medical University), Huanwei Zheng(Hebei Medical University), Erhei Dai(Hebei Medical University), Luyi Tian(The University of Melbourne), Mai‐Juan Ma(Institute of Microbiology)
Signal Transduction and Targeted Therapy
September 16, 2021
Cited by 55Open Access
Full Text

Abstract

Abstract While some individuals infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present mild-to-severe disease, many SARS-CoV-2-infected individuals are asymptomatic. We sought to identify the distinction of immune response between asymptomatic and moderate patients. We performed single-cell transcriptome and T-cell/B-cell receptor (TCR/BCR) sequencing in 37 longitudinal collected peripheral blood mononuclear cell samples from asymptomatic, moderate, and severe patients with healthy controls. Asymptomatic patients displayed increased CD56 bri CD16 − natural killer (NK) cells and upregulation of interferon-gamma in effector CD4 + and CD8 + T cells and NK cells. They showed more robust TCR clonal expansion, especially in effector CD4 + T cells, but lack strong BCR clonal expansion compared to moderate patients. Moreover, asymptomatic patients have lower interferon-stimulated genes (ISGs) expression in general but large interpatient variability, whereas moderate patients showed various magnitude and temporal dynamics of the ISGs expression across multiple cell populations but lower than a patient with severe disease. Our data provide evidence of different immune signatures to SARS-CoV-2 in asymptomatic infections.


Related Papers